A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

Inclusion Criteria: * Hematocytologically or pathohistologically proven adult T-cell leukemia/lymphoma with positivity of anti-HTLV-1 antibody (Aggressive subtypes: acute, lymphoma type, or chronic type with unfavorable factor) * Age: 20-85 * Meeting the any following criteria for screening * Relapsed or recurrent ATL have history of treatment with mogamulizumab * At least one regimen of chemotherapy in case of intolerance/contraindication for mogamulizumab * Relapsed or recurrent ATL judged inadequate of treatment with mogamulizumab by investigators * Relapsed or recurrent ATL after allogeneic hematopoietic stem cell transplantation * Having peripheral blood lesion * ECOG performance status: 0-2 * T-Bil: =\< ULNx2, AST and ALT: =\< ULNx2.5 * Expected more than 3 months of survival Exclusion Criteria: * Body Weight \< 35kg * Hemoglobin \< 10g/dL * Splenomegaly * Subjects who received an following therapy * Chemotherapy or molecular-targeted agent for ATL : within 28 days prior to registration * Radiotherapy : within 28 days prior to registration * Any investigational drugs or medical devices (unapproved in Japan) : within 28 days prior to registration * Autologous stem cell transplantation : within 84 days prior to registration * Allogenic stem cell transplantation : within 100 days prior to registration * Administrated 5-ALA drug except study drug within 7 days prior to registration * Ate the foods containing 5-ALA or St. John's wort within 7 days prio…